Price movement over the last 24 hours
Global X Artificial Intelligence & Technology ETF vs Zimmer Biomet Holdings Inc — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $62.53, while Zimmer Biomet Holdings Inc trades at $87.68 (market cap $17.30B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while Global X Artificial Intelligence & Technology ETF pays none, and Global X Artificial Intelligence & Technology ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| AIQ | ZBH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $107.71 |
52-Week Low | $43.28 | $79.58 |
Market Cap | — | $17.30B |
Enterprise Value | — | $24.34B |
Dividend Yield | — | 1.07% |
Signals from Pluang's Aura AI — not financial advice
AIQ trades at $63.84, up 3.22% with a neutral technical signal. The ETF shows strong momentum with moving averages indicating bullish sentiment while oscillators remain neutral. Recent performance highlights include turning $10,000 into $13,400 over six months, outperforming broader market indices. The fund has gained attention for its AI-focused strategy amid expanding market interest beyond mega-cap technology stocks.
The outlook remains positive as AI adoption accelerates, though valuations require monitoring. Key risks include thematic ETF concentration and fee structure considerations. Institutional interest in AI infrastructure spending supports long-term growth potential, but market volatility around AI stock rotations presents near-term challenges.
Zimmer Biomet (ZBH) trades at $89.41, up 2.22% with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with 70% gross margins and revenue growth to $8.23B in 2025, though net margins compressed to 8.56%. Recent developments include a $140M acquisition and plans to hire 500 tech employees in India, supporting growth initiatives. Valuation metrics appear reasonable with P/E of 23.25 and P/S of 2.11.
ZBH offers moderate upside to the $98.33 consensus target with analyst sentiment mixed (43% buy, 50% hold). Key risks include rising debt levels (debt-to-asset ratio increased to 32.57% in 2025) and margin pressure. The company's $1B share repurchase program and dividend provide shareholder returns, but execution on growth initiatives remains critical for sustained outperformance.
Trailing returns across standard periods
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →